Jin Medical (ZJYL) Fundamental Analysis: Revenue, Earnings & Valuation

8.62 / 10

Outperform

Fundamental analysis rates Jin Medical as Outperform (8.6/10). Key drivers include ROA 2.79% (group 4, Q 0.0093), annualized asset margin 2.79% (group 4), and cash‑flow‑to‑revenue 14.04% (group 4). Net‑profit‑to‑total‑profit is weaker (group 2, negative weight), slightly dragging the score.

Analysis Checks(5/6)

ROA (%)

Value2.79

Score3/3

Weight28.97%

1M Return1.81%

Net cash flow from operating activities / Operating revenue (%)

Value14.04

Score3/3

Weight26.70%

1M Return1.63%

Annualized net profit margin on total assets (%)

Value2.79

Score3/3

Weight28.97%

1M Return1.81%

EBIT / Total operating revenue (%)

Value3.90

Score3/3

Weight24.78%

1M Return1.53%

Net profit / Total operating revenue (%)

Value6.68

Score2/3

Weight19.71%

1M Return1.26%

Net profit / Total profit (%)

Value86.55

Score1/3

Weight-29.13%

1M Return-2.39%

Is ZJYL fundamentally strong?

ZJYL scores 8.62/10 on fundamentals and holds a Discounted valuation at present. Backed by its 4.10% ROE, 6.68% net margin, 12.16 P/E ratio, 0.49 P/B ratio, and -50.00% earnings growth, these metrics solidify its Outperform investment rating.